Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Disrupting monocytic AML and monocytic leukemia stem cells with a novel cladribine regimen: From bench to bedside

View Full Paper
Ask AI
Bookmark
Share

Authors

JHJia HuJHJingyi HuangWZWeiyan Zheng

Discussion

Loading...

Member takes

Overview

Clinical trial demonstrates cladribine's efficacy against AML, targeting resistant leukemia stem cells and suggesting improved outcomes.

Key Points

  • CHA regimen effectively reduced engraftment in mono-AML while sparing prim-AML, highlighting its selectivity.
  • Single-arm clinical trial showed a leukemic complete response rate of 76.2% in the mono-AML subgroup, comparable to prim-AML rates.
  • Treatment with cladribine and Homoharringtonine led to lower treatment-related mortality, emphasizing safety.
  • The study reveals unique mechanisms of therapeutic resistance in leukemia stem cells, indicating lineage-specific vulnerabilities.

Cite This Study

Hu et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce3https://doi.org/10.1182/blood-2025-1508
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia2025
  2. 2Efficacy of a venetoclax-based, anthracycline-free regimen in newly diagnosed CBFβ::MYH11(+) acute myeloid leukemia2025
  3. 3Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory Acute Myeloid Leukemia2025
  4. 4Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study2025
  5. 5Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional “3+7” intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial2025